Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

Roger von Moos,Arnaud Roth,Thomas Ruhstaller,Lucas Widmer,Catrina Uhlmann,Richard Cathomas,Dieter Köberle,M. Simcock,Doris Lanz,Razvan Popescu

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

2010

Roger von Moos
Arnaud Roth
Thomas Ruhstaller
Lucas Widmer
Catrina Uhlmann
Richard Cathomas
Dieter Köberle
M. Simcock
Doris Lanz
Razvan Popescu

Background: A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer. Patients and

Keywords:

Capecitabine
Colorectal cancer
Progression-free survival
General surgery
Performance status
Irinotecan
Oxaliplatin
Medicine
first line treatment
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations